Clinical Trial: Cancer, Lung Cancer

Lung Cancer A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Full Name

An Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial

Description

If you meet all eligibility requirements and choose to participate, a genetic test will be done to learn if your tumor has any genetic changes (specifically, genetic changes in ALK and EGFR). ALK and EGFR are both proteins found on the surface of cells. If your tumor is found to have one of these genetic changes, you may be invited to participate in a trial that will look at drugs which may target tumors that have these specific genetic changes. After you tumor tissue is screened, if there is any tissue left, the remainder of your coded tissue samples will be sent to a National Cancer Institute (NCI) sponsored storage facility, currently known as the Biospecimen Core Resource (BCR) where the samples will be processed. Portions of your samples will then be sent to different types of laboratories, all within the NCI facility, as part of this project. If you cancer comes back and there is biopsy tissue available for analysis, it too will be studied in that way. One type of laboratory will analyze your DNA by a method called sequencing. Other types of laboratories will study other biochemical material from your samples by different methods. Any remaining portions of your sample will be stored at the BCR for possible future use in research.

Eligibility

Inclusion Criteria
Must be greater than or equal to 18 years of age Must have an ECOG Performance Status of 0-1 Must not have had prior treatment with agents targeting EGFR mutation or ALK rearrangement Must have completely resected non-squamous non-small cell lung cancer
Doctor(s) Running This Study